SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking community discussion about potential liquidations and a possible shift to a bear market. Some believe the dip presents a buying opportunity, while others express concerns about market manipulation and the influence of major players like Michael Saylor and MicroStrategy. Privacy coins like ZEC are gaining traction as a potential hedge against BTC's volatility.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The $SLAP crypto community is buzzing with activity, emphasizing their strong community and meme-driven approach. Discussions also highlight real-world partnerships, such as sponsoring MMA fighters and events, to build a global brand. The community is focused on staying active and supporting each other, regardless of market conditions, using phrases like '$WAGMI' and uniting the memes.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid community discussions surrounding newly surfaced Epstein emails and speculation about the potential release of related files. Investors are expressing concerns about the implications of these developments, while others highlight broader concerns about the company's financials and the potential impact of political events. Community members are actively debating the company's valuation and future prospects.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending amid discussions around its Bitcoin holdings and Michael Saylor's media appearances, with debates on whether recent price movements signal a buying opportunity or a potential downturn. Community chatter includes speculation on Saylor's strategy, potential impacts of Bitcoin's price fluctuations on the stock, and concerns about debt and dilution.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors discuss the potential impact of defense contracts, with particular attention to the Black Widow drone and the company's maritime division. Community members are weighing the implications of recent earnings, revenue guidance, and government spending.  Broader conversations involve comparing Red Cat to other drone companies and analyzing potential catalysts like government contracts and the upcoming earnings report.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to a proposed acquisition by Merck, sending the stock soaring; however, some community members speculate the company could garner a higher offer and are hoping for a bidding war. Bullish investors are discussing the potential for shareholders to reject the current offer, while others are pointing to the recent data and the potential for a buyout.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's partnership with Gopuff for cash delivery sparks debate about its practicality and expansion into financial services. Community members are actively discussing the stock's correlation with Bitcoin and overall market volatility, especially after a recent dip despite strong October metrics. Some traders see the dip as a buying opportunity, while others express concern over market manipulation and the stock's future direction.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid market volatility, with community debates raging about whether the dip presents a buying opportunity or signals further downside. Discussions include concerns about whale activity and potential market manipulation, while some traders point to positive developments like the Fusaka upgrade and potential ETH ETF staking. Despite the uncertainty, there remains strong conviction from some members regarding Ethereum's long-term potential and dominance in the crypto space.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its meme-driven narrative of financial resilience. Recent engagement focuses on community building and the concept of rebelling against a "broken system", alongside community-driven NFT contests. Social media teases and website updates suggest potential future developments and further fuel community excitement.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending amidst Bitcoin's price volatility, influenced by factors like potential government shutdowns and large liquidations. Community discussions revolve around Bitcoin's support levels, potential for a price drop below key thresholds, and its relationship with traditional assets like gold. Some traders are expressing concerns about a potential bear market, while others remain bullish, awaiting new highs.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat.com...

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

Equity

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer Trinity Capital Inc. Provides $130 Million in...

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced">granted</a> Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate CAN-2409 for the treatment of a certain kind of prostate cancer.CAN-2409 is being studied for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and was previously granted FDA Fast Track designation for the same indication.RMAT designations are intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.Candel’s lead candidate was granted the designation based on positive data from a late-stage trial evaluating the efficacy and safety of the investigational drug plus a prodrug, together with external beam radiation therapy, in newly diagnosed, localized, intermediate-to-high-risk prostate cancer.Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application (BLA) seeking permission to commercialize. The company is looking to submit the application by the end of 2026.RMAT designations offer the company access to mechanisms designed to fast-track BLA review and approval.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_10_27_02_AM_png_786b86992f.webp" alt="CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits " width="628" height="63"><figcaption>CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user opined that the shares are suitable for holding in the mid- to long-term.<stembedurl>https://stocktwits.com/Bowlofpasta/message/616040223</stembedurl>According to data from Koyfin, all three analysts covering CADL rate it a ‘Buy.’ The stock has an average price target of $21.67, implying an upside of over 200% from its current value.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> is down by about 33% this year and by about 30% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/macys-q1-earnings-tops-estimates/ch0okCjRbsh">Macy’s Q1 Earnings Top Estimates, But Company Cuts 2025 Guidance Over Tariff Concerns, Weaker Consumer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy

Best Momentum Stocks to Buy for May 19th

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's  What You Should Know

Shares of Candel Therapeutics, Inc. (CADL) surged nearly 10% on Tuesday afternoon after the company reported upbeat first-quarter (Q1) earnings.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results">reported</a> diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024, and surpassing an estimated loss of $0.35 per share, as per Finchat data.It said the rise in net income was primarily related to the change in the fair value of the company’s warrant liability.While research and development expenses narrowed year-on-year in the quarter, general and administrative expenses rose.The biopharmaceutical company ended the first quarter with cash and cash equivalents of $92.2 million compared to $102.7 million as of Dec. 31, 2024. Candel expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.CEO Paul-Peter Tak said that the company’s primary focus for 2025 remains working toward submitting an application to the U.S. Food and Drug Administration (FDA) for the commercialisation of its investigational immunotherapy candidate and lead asset CAN-2409 for the treatment of prostate cancer. The submission is expected in the fourth quarter of 2026.“We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer,” he said.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel rose within the ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_41_07_PM_png_6a3877db5b.webp" alt="CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CADL/sentiment">CADL stock</a> is down by about 39% this year and 46% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-google-uber-stocks-rally-after-committing-to-invest-80-b-in-600b-us-saudi-deal/chi8AJjRbZN">AMD, Google, Uber Stocks Rally After Committing To Invest $80B As Part Of US-Saudi $600B Trade Pact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc